Biogen Wins OK for Psoriasis Drug
- Share via
From Times Wire Services
Biogen Inc. won U.S. approval to sell a treatment for psoriasis that lacks side effects of older drugs and could bring it $500 million in annual sales.
Amevive, an injected medicine, won Food and Drug Administration clearance for patients with a form of the skin disease called moderate-to-severe chronic plaque psoriasis.
The drug is expected to face competition from Amgen Inc.’s arthritis drug Enbrel, which is being studied as a psoriasis treatment.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
